Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
about
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and preventionThe Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer PatientsMicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor β-activated kinase 1SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patientsThe potential for liquid biopsies in the precision medical treatment of breast cancer.microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection.Circulating microRNA-based screening tool for breast cancer.Examining plasma microRNA markers for colorectal cancer at different stages.Endothelial and circulating C19MC microRNAs are biomarkers of infantile hemangioma.miR146a-mediated targeting of FANCM during inflammation compromises genome integrity.Blood and lung microRNAs as biomarkers of pulmonary tumorigenesis in cigarette smoke-exposed mice.Bone morphogenetic protein 4 regulates microRNA expression in breast cancer cell lines in diverse fashion.Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.Role of micro-RNAs in breast cancer surgery.A Semi-Supervised Learning Algorithm for Predicting Four Types MiRNA-Disease Associations by Mutual Information in a Heterogeneous Network.miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers.A pilot study on plasma levels of micro-RNAs involved in angiogenesis and vascular maturation in patients with breast cancer.Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patientsBranched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detectionExosomal microRNAs as tumor markers in epithelial ovarian cancerLiquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
P2860
Q26742027-8256CC9F-E563-4978-91F0-8209C3D9052CQ26782449-FE80131C-1C9C-483F-979D-FA348B2760C3Q33828286-460E545E-7A91-4E54-9942-614C696ACF51Q35866423-48C930ED-9B97-4EEF-94AB-CD1C6251C908Q36385805-9AC7C18E-CF3C-4CB8-8504-DC93B4833D26Q36750596-56F6BE03-9839-490E-8C37-830A0338A250Q36849660-9AFDB307-5FFC-4D7D-B6BA-12A8DE38D180Q36902655-5E066760-F67A-4631-B12B-C88623F401E2Q36905676-C5F976B7-C2BF-49D9-8AC4-E1500D2F767EQ36998271-7B651D6D-F4EB-4B60-9F37-AA27EA42608BQ37268517-F0FBED9F-A0EA-457C-8742-4CFEB22B8883Q37564625-A27E6178-6473-4270-89F8-9D163E32287DQ37686233-507E97DD-B1C4-4F97-8624-4A465599581AQ38810546-20023705-B458-40BE-9184-8BF5485E3615Q38842894-0675BE9C-10C3-4CAD-BBA0-532C9646DFA3Q41954466-8DA66614-386A-45F1-BABE-C437B2189BACQ42370321-A2EF17D8-5237-4E0E-9550-B885AA0ADDC1Q47629674-5741BFC1-51EC-404D-BDBC-09662B5DD9B3Q47728281-BD28A9BE-F5E3-41E1-8285-D8B6E6623E0DQ50421175-ED9404A0-BE22-4A9F-8CEF-7CD19A5B54F4Q51182190-A20EA591-A1F5-4B88-A4E8-4249059A3977Q51213425-BA00ECFD-7274-4795-9561-0410B06CEA5FQ58699582-579D5300-AD58-481E-B4F6-95D19DA18F83Q58733916-2FF5916C-6B24-43E7-ACE2-95F935F2B9A4Q58776553-F8841CA3-7DE4-4C56-A35D-C5BE22145AEBQ58799160-DB20A644-292E-4ACD-BC73-9D950F639EB6
P2860
Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@ast
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@en
type
label
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@ast
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@en
prefLabel
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@ast
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@en
P2093
P2860
P356
P1433
P1476
Aberrant plasma levels of circ ...... tus of breast cancer patients.
@en
P2093
Bernadette Jäger
Brigitte Rack
Heidi Schwarzenbach
Isabel Stückrath
Klaus Pantel
Wolfgang Janni
P2860
P304
13387-13401
P356
10.18632/ONCOTARGET.3874
P407
P577
2015-05-01T00:00:00Z